Phase 1B Clause Samples

Phase 1B. Figure 10: Golden Glades Lot Utilization vs. Route 95X Ridership Table 17: Park and Ride Lot Utilization for New 95 Express Bus Routes

Phase 1B. The goals of Track 2, phase 1B are similar to those of Track 1 phase 1B. In addition to examining the interaction of other Track 2 assays, Track 2 phase 1B will require examining interactions with Track 1 assays. Track 2, phase 1B should last 6 months. Following establishment of Track 2 assays and the acquisition of data regarding the interaction of both Track 1 and Track 2 assays, a working protocol will be assembled for all chosen assays. *** As described for Phase 2 of Track 1 *** lines will be tested in Phase 2 of Track 2. *** of these line will be Pfizer-supplied KO lines on a *** and *** will be *** from an outsource breeder. One of the *** cohorts will be just *** mice and one will be a *** with ***. As with Phase 2 of Track 1, delivery to Xenogen Cranbury will be made for one of the *** lines, at 1-week intervals for *** weeks at the start of phase 2. In this case, *** KO mice and *** will be supplied or for the *** mice a cohort of *** mice will be supplied *** of which will serve as untreated controls and another *** which will serve to be treated with validation reagents as outlined in Appendix 1. Xenogen Cranbury should complete a full phenotypic protocol on each line within *** months after receiving a given KO line. ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇ will last approximately *** months. We anticipate that following Phase 2, as we proceed to full scale production phenotyping, the number of *** may be reduced. These decisions will be made on an assay by assay basis, following discussions with the associated TA and scientists at Xenogen. ***. The cost of phenotypic analysis using all Track I and Track II Assays under this Research Plan is at a rate of *** per Transgenic Mouse Line. *** *** CONFIDENTIAL TREATMENT REQUESTED *** CONFIDENTIAL TREATMENT REQUESTED *** CONFIDENTIAL TREATMENT REQUESTED December 11, 2003 Xenogen Biosciences ▇ ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ Attn: Mr. ▇▇▇ ▇▇▇▇▇▇ Dear ▇▇. ▇▇▇▇▇▇, I am writing to confirm that the parties have agreed that additional research activities will be carried out under the Collaborative Research Agreement dated December 28, 2000 (“2000 Agreement”). Accordingly, the Research Plan will be amended pursuant to Sections 1.16 and 13.4 of the 2000 Agreement to include the activities described in the attached document, which will be appended to the 2000 Agreement as Exhibit C, and Section 1.13 is hereby amended by revising the second sentence to read, “as Exhibits A and C.” The amount and payment schedule of fees payab...

Phase 1B. Phase 1B shall mean that portion of the construction work identified in the ▇▇▇▇▇▇ ▇▇▇▇ 2018 Bid Set Plans entitled SFCT – Cargo Yard Densification (eRTGs) Phase 1, Project No. 2017—034 designated as Phase 1B work whereby Operator’s capacity will be reconfigured from an estimated 182,000 container moves to an estimated 232,000 container moves, to include 231 additional refrigerated container units (including storage area and electrical connections) for a total of 657 units. Phase 1B will be accomplished by the addition of those programmatic elements which appear in the attached Exhibit C and will be completed in accordance with the Project Schedule.

Phase 1B. PRELIMINARY DESIGN AND NEPA This phase includes the preliminary design (30% Plans) for the site as well as the NEPA environmental document including public engagement and preliminary agency coordination. The preliminary design for the selected Bridge Architectural Concept will continue focused on informing the preliminary plans and preliminary cost estimate.

Phase 1B. Condition Assessment 1. Conduct an onsite assessment of the structures to assess the physical condition of structural, and operational systems The assessment will include a visual observation to review floors, columns, beams, concrete shells, tie beam and other structural elements. This observation will be directed to confirm construction conditions found in the document review and/or to obtain construction information not available in the documents. Unless agreed otherwise, the observation will be limited to those portions of the structure which are exposed and readily observable without the removal of existing finishes. The visual review will document noticeable distress such as cracks, leaks, spalls, scaling, corrosion of reinforcing bars and structural steel elements, distress of architectural elements, and other similar adverse conditions. 2. Evaluate field testing, material testing and non-destructive testing of selective concrete members. The scope and extent of the testing will be coordinated to determine viable repair approaches and alternatives. The following field and laboratory test will be considered in the development of the testing program. a. Concrete petrographic (microscopic) examination of concrete core samples to evaluate the general concrete quality and to identify cause of concrete deterioration: b. Chloride ion content of concrete core samples at equal increments to determine the chloride contamination at various depths of the roof concrete shell. c. Concrete compressive strength examination of concrete core samples. The suggested testing program is outlined as follow: Petrographic exam Core 16 (8 Per Hangar) Chloride ion content Core 16 (8 Per Hangar) Compressive Strength Core 8 (4 Per Hangar) 3. Perform a field survey and plumbing code review to determine if adequate drainage systems are provided at the parabolic roofs. 4. Perform an elevation survey of the roof to determine if the roof structures have any unusual deflection or sagging. A minimum of 10 monitoring prism targets will be installed for each hangar. The monitoring prism targets will be used to establish baseline measurement for future monitoring of the roof. 5. Remove and replace boxes covering the tie beam anchorages, including removal and replacement of the grease inside each box. 6. Perform moisture evaluation along the unbonded Post Tension (PT) tendons of the tie beam, to determine if there is sufficient moisture to initiate corrosion activity. 7. Remove broken wir...

Phase 1B. IMPLEMENTATION STRATEGY ROADMAP

Phase 1B. Upon successful completion of Phase 1b as set forth in Section 2.1 and the Development Plan SNT shall and hereby does grant to SONY the exclusive right for a period of sixty (60) days (the “Negotiation Period”) to negotiate with SNT in good faith and in timely fashion for the exclusive rights to further develop and supply to SNT the Products having specifications the same as or substantially similar to the Specifications resulting from Phase 1b of the Development Plan. For the avoidance of doubt, (i) the foregoing right of negotiation for SONY’s appointment as exclusive developer or exclusive supplier of Products to SNT shall apply only to the Products that are the subject of the Development Plan (and any Products with the same or substantially similar specifications) and not to any instrumentation or other product developed or sold by SNT, and (ii) if SONY and SNT are unable to enter into a written agreement with mutually agreeable terms for the exclusive development and/or supply of the applicable Product, including the rights and responsibilities under Phase 2, by the expiration of the Negotiation Period, then neither Party shall have any liability to the other Party with respect to such Product save as to clause 8 (Confidentiality) and payment by each Party of any contributions specified in that part of the Development Plan relating to Phase 1b as being the responsibility of that Party.

Phase 1B. The Lessor shall prepare and deliver, at the Lessor’s own expense, final working plans and complete construction drawings for both building standard and above standard tenant improvements for Phase “1B” within forty-five (45) days of the receipt by the lessor of design intent drawings from GSA.

Phase 1B. Part 1 The cell lines and cDNA constructs approved by the Joint Research Committee for Phase 1B – Part 1 (a) have been acquired by, or on behalf of the Company (including any related Required Third Party Intellectual Property Rights) and (b) the Company has taken delivery of such cell lines and cDNA constructs within three months of the Effective Date. Phase 1B – Part 2 The Joint Research Committee has approved at least one cell line for use as the parental cell line for the generation of the Rheoswitch neuroblastoma cell line by CMT within six months of the Effective Date. The Foundation and CMT have executed the CMT Agreement within twelve months of the Effective Date. Phase 1B – Part 3 CMT has delivered the Rheoswitch neuroblastoma cell line to the Company within 12 months of the execution of the CMT ▇▇▇▇▇▇▇▇▇. ▇▇▇▇▇ ▇▇ The cell lines and htt specific antibodies approved by the Joint Research Committee for ▇▇▇▇▇ ▇▇ (▇) have been acquired by, or on behalf of the Company (including any related Required Third Party Intellectual Property Rights) and (b) the Company has taken delivery of such cell lines and cDNA constructs within three months of the Effective Date. Phase 2 and 3 – Use of Assay 1 for Screening Complete optimization of Assay 1 within four months following the date the Company has taken delivery of the cell line approved by the Joint Research Committee for use in the optimization of Assay 1. Assay 1 meets each of the specifications set forth in Appendix A and is approved by the Joint Research Committee for use in Phase 2 and 3. Phase 2 and 3 – Use of Assay 2 for Screening Complete development and optimization of Assay 2 within five months following the delivery of the Rheoswitch neuroblastoma cell line to the Company. Assay 2 meets each of the specifications set forth in Appendix A and is approved by the Joint Research Committee for use in Phase 2 and 3. Phase 2 and 3 – Use of Assay 3 for Screening Complete development and optimization of Assay 3 within nine months following the date cell lines and htt specific antibodies approved by the Joint Research Committee for use in the development and optimization of Assay 3 are acquired by, or on behalf of, the Company. Assay 3 meets each of the specifications set forth in Appendix A and is approved by the Joint Research Committee for use in Phase 2 and 3. Phase 2A The Company has (a) selected at least 1,300 Company Library Compounds within one month of the approval by the Joint Research Committee of a...